Tag: DISRUPT PAD III
Shockwave IVL maintains ‘superiority’ to angioplasty in calcified peripheral disease at...
Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to excellent long-term outcomes...
Intravascular lithotripsy ‘superior’ to PTA in acute procedural success out to...
The DISRUPT PAD III randomized controlled trial (RCT) provides the largest level-one evidence for the treatment of heavily calcified femoropopliteal arteries, noted William Gray,...